Among those who saw trouble brewing for stocks last year was strategist Warren Pies, who warned clients in December that the S&P 500 faced a 10% correction in the first half of 2025.

Halozyme Therapeutics is suing Merck for patent infringement. The San Diego biotechnology company said Thursday it believes a proposed form of Merck's cancer medicine Keytruda uses a formulation that ...